Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Cochlear ( (AU:COH) ).
Cochlear Limited has updated its FY25 earnings guidance due to slower-than-expected sales growth, projecting an underlying net profit of $390-400 million. The company anticipates a decline in Services revenue by low double-digits, despite efforts to boost sales with new products like the Nucleus® Kanso® 3 Sound Processor. While cochlear implant units are expected to grow by 10%, growth in developed markets has been hindered by slower market expansion and minor market share losses. The launch of a new cochlear implant system in Europe and Asia Pacific is set for mid-June 2025, with further expansion pending regulatory approvals.
The most recent analyst rating on (AU:COH) stock is a Buy with a A$311.00 price target. To see the full list of analyst forecasts on Cochlear stock, see the AU:COH Stock Forecast page.
More about Cochlear
Cochlear Limited is a company operating in the medical device industry, primarily focused on developing and manufacturing implantable hearing solutions. Its main products include cochlear implants and sound processors, targeting individuals with hearing impairments. The company has a significant market presence, with a focus on both developed and emerging markets.
Average Trading Volume: 190,089
Technical Sentiment Signal: Hold
Current Market Cap: A$17.63B
For a thorough assessment of COH stock, go to TipRanks’ Stock Analysis page.